Craneware plc vs GoodRx
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- GoodRx is the larger company by market value: $1.2 B against $1.0 B for Craneware plc, 1.1 times as much (market caps of Aug 1, 2026 for Craneware plc and Oct 14, 2026 for GoodRx). Craneware plc's value is the last on file, from Aug 1, 2026: no market-data feed is connected for its exchange yet.
- GoodRx had more revenue: $797 M in the year to December 2025 against $165 M for Craneware plc in the year to June 2022.
- GoodRx earned more: net income of $30 M against $9 M for Craneware plc.
- Craneware plc keeps more of each dollar of sales: a net margin of 5.5% against 3.8% for GoodRx.
- On price to earnings, Craneware plc trades at 113.8× and GoodRx at 72.4×: investors pay more for each dollar of Craneware plc's profit.
Market value, the same start = 100
From Jan 2021: how each one's value moved, whatever its size.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | Craneware plc CRW.L · #9,217 in the world | GoodRx GDRX · #8,585 in the world |
|---|---|---|
| Profile | ||
| Country | 🇬🇧 UK | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Healthcare Information Services | Healthcare Information Services |
| Founded | — | 2011 |
| Size | ||
| Market cap | $1.0 B | $1.2 B |
| Revenue | $165 M | $797 M |
| Net income | $9 M | $30 M▲ best |
| Employees | — | 954 |
| Valuation | ||
| P/E ratio | 114× | 72.4× |
| Price to sales | 6.2× | 1.5× |
| Price to book | 3.1× | 1.9× |
| Free cash flow yield | — | 14.0% |
| Profitability | ||
| Operating margin | — | 11.0% |
| Net margin | — | 3.8% |
| Return on equity | — | 4.5% |
| Return on invested capital | — | 5.8% |
| Growth | ||
| Revenue growth | — | 0.6% |
| Revenue growth, 3 years a year | — | 1.3% |
| Earnings per share growth | — | 125.0% |
| Financial strength | ||
| Debt to equity | — | 0.8× |
| Net debt to EBITDA | — | 1.4× |
| Cash | ||
| Free cash flow margin | — | 20.6% |
| Shareholder returns | ||
| Shareholder yield | — | 18.4% |
| Altman Z-score zone | — | distress |
| Data as of | Market cap Aug 2026 | Market cap Oct 2026; ratios FY2025 |
Questions and answers#
Which is bigger, Craneware plc or GoodRx?
GoodRx is the larger company by market value: $1.2 B against $1.0 B for Craneware plc, 1.1 times as much (market caps of Aug 1, 2026 for Craneware plc and Oct 14, 2026 for GoodRx). Craneware plc's value is the last on file, from Aug 1, 2026: no market-data feed is connected for its exchange yet.
Which makes more money, Craneware plc or GoodRx?
GoodRx had more revenue: $797 M in the year to December 2025 against $165 M for Craneware plc in the year to June 2022. GoodRx earned more: net income of $30 M against $9 M for Craneware plc.
Which is more profitable, Craneware plc or GoodRx?
Craneware plc keeps more of each dollar of sales: a net margin of 5.5% against 3.8% for GoodRx.
Is Craneware plc cheaper than GoodRx?
On price to earnings, Craneware plc trades at 113.8× and GoodRx at 72.4×: investors pay more for each dollar of Craneware plc's profit. A lower multiple is not by itself a better buy: it also reflects expected growth, risk and accounting.